Form 4: BioXcel CFO Executes RSU Vesting and Tax Sale

BioXcel Therapeutics CFO Richard Steinhart reported the vesting of 17,500 RSUs and a subsequent sale of 6,845 shares to cover tax obligations.

Summary

• CFO Richard Steinhart acquired 17,500 shares of common stock on May 4, 2026, through the vesting of Restricted Stock Units (RSUs).
• On May 20, 2026, the CFO sold 6,845 shares at a weighted average price of $1.085 per share.
• The sale was conducted under a Rule 10b5-1 trading plan specifically to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, the CFO holds 26,300 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a discretionary change in investment position.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to equity management.
• The sale was limited to the amount necessary to cover tax liabilities, suggesting continued long-term alignment with the company.

Negatives

• The sale of shares, even for tax purposes, reduces the direct equity stake held by the CFO.

Risks

• The reporting person remains subject to the company's performance and market volatility as a significant shareholder.
• Future vesting and tax obligations may necessitate further sales of common stock.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the reporting of insider equity transactions.

Management Comments

• The reporting person confirms the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 3, 2026, solely to cover taxes due in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that routine insider sales for tax withholding purposes are standard corporate practice and generally do not signal a change in management sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a best-practice standard for corporate executives to avoid potential conflicts of interest or accusations of insider trading.
• The sale of shares to cover tax obligations upon RSU vesting is a common and expected event for executives in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and limited to tax obligations.

Next Steps

• Continued monitoring of future Form 4 filings for any discretionary changes in insider holdings.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Insider Trading, Form 4, CFO, Equity Compensation